Combining CXCL10 Gene Therapy and Radiotherapy Improved Therapeutic Efficacy in Cervical Cancer HeLa Cell Xenograft Tumor Models

Overview

Journal Oncol Lett

Specialty Oncology

Date 2015 Dec 2

PMID 26622567

Citations 14

Authors

Ming Zhao

Qian Ma

Jinhui Xu

Shaozhi Fu

Lanlan Chen

Biqiong Wang

Jingbo Wu

Linglin Yang

Affiliations

Soon will be listed here.

Abstract

Radiotherapy is an important treatment method for cervical cancer, but the efficacy requires improvement. Therefore, novel methods of treatment are required. Previous data have demonstrated that the CXC chemokine ligand 10 (CXCL10) inhibits angiogenesis, induces apoptosis and causes avoidance of the S phase of the cell cycle in cervical cancer cells. The aim of the present study was to evaluate the anti-tumor effect of radiotherapy combined with CXCL10 gene therapy. Mouse models of cervical carcinoma were created by inoculation with HeLa cells, and were treated by combining intravenously administered plasmid-encoding CXCL10, administered 5 times (days 12, 15, 18, 21 and 24 following inoculation), with direct radiation (20 Gy/5 fractions) administered on 5 consecutive days (~day 27 after inoculation). The vessel density and tumor cell proliferation were observed by immunostaining, and apoptosis was determined using a TUNEL assay. The results revealed a significant increase in the inhibition of tumor growth, reduced vessel density, decreased cell proliferation and increased apoptosis in the tumor cells of the combination therapy group. Overall, these findings resulted in the conclusion that CXCL10 gene therapy in combination with radiotherapy is a novel effective therapeutic strategy for cervical cancer.

Citing Articles

Radiomics Signatures Based on Computed Tomography for Noninvasive Prediction of CXCL10 Expression and Prognosis in Ovarian Cancer.

Wang X, Xing Y, Zhou X, Wang C, Han S, Zhao S Cancer Rep (Hoboken). 2024; 7(10):e70030.

PMID: 39443817 PMC: 11499071. DOI: 10.1002/cnr2.70030.

Hub genes and their key effects on prognosis of Burkitt lymphoma.

Xu Y, Wang G, Zhang M, Yang J World J Clin Oncol. 2023; 14(10):357-372.

PMID: 37970111 PMC: 10631346. DOI: 10.5306/wjco.v14.i10.357.

The Value of CXCL1, CXCL2, CXCL3, and CXCL8 as Potential Prognosis Markers in Cervical Cancer: Evidence of E6/E7 from HPV16 and 18 in Chemokines Regulation.

Fernandez-Avila L, Castro-Amaya A, Molina-Pineda A, Hernandez-Gutierrez R, Jave-Suarez L, Aguilar-Lemarroy A Biomedicines. 2023; 11(10).

PMID: 37893029 PMC: 10604789. DOI: 10.3390/biomedicines11102655.

Ionizing Radiation Selectively Increases CXC Ligand 10 Level via the DNA-Damage-Induced p38 MAPK-STAT1 Pathway in Murine J774A.1 Macrophages.

Seo Y, Baik J, Lee S, Lee J, Ahn H, Lim M Cells. 2023; 12(7).

PMID: 37048082 PMC: 10093567. DOI: 10.3390/cells12071009.

Human induced pluripotent stem cell engineering establishes a humanized mouse platform for pediatric low-grade glioma modeling.

Anastasaki C, Chatterjee J, Cobb O, Sanapala S, Scheaffer S, Costa A Acta Neuropathol Commun. 2022; 10(1):120.

PMID: 35986378 PMC: 9392324. DOI: 10.1186/s40478-022-01428-2.

References

Small Jr W, Mell L, Anderson P, Creutzberg C, De los Santos J, Gaffney D . Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys. 2007; 71(2):428-34. PMC: 2752724. DOI: 10.1016/j.ijrobp.2007.09.042. View

Luster A, Unkeless J, Ravetch J . Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature. 1985; 315(6021):672-6. DOI: 10.1038/315672a0. View

Mazumder S, Plesca D, Almasan A . A jekyll and hyde role of cyclin E in the genotoxic stress response: switching from cell cycle control to apoptosis regulation. Cell Cycle. 2007; 6(12):1437-42. PMC: 2522303. DOI: 10.4161/cc.6.12.4432. View

Xiao F, Wei Y, Yang L, Zhao X, Tian L, Ding Z . A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther. 2002; 9(18):1207-13. DOI: 10.1038/sj.gt.3301788. View

Mandelblatt J, Lawrence W, Womack S, Jacobson D, Yi B, Hwang Y . Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002; 287(18):2372-81. DOI: 10.1001/jama.287.18.2372. View

Campanella G, Colvin R, Luster A . CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PLoS One. 2010; 5(9):e12700. PMC: 2938333. DOI: 10.1371/journal.pone.0012700. View

Han G, Suzuki K, Koike H, Suzuki K, Yoneyama H, Narumi S . IFN-inducible protein-10 plays a pivotal role in maintaining slit-diaphragm function by regulating podocyte cell-cycle balance. J Am Soc Nephrol. 2005; 17(2):442-53. DOI: 10.1681/ASN.2004090755. View

Klopp A, Eifel P . Chemoradiotherapy for cervical cancer in 2010. Curr Oncol Rep. 2010; 13(1):77-85. DOI: 10.1007/s11912-010-0134-z. View

Feldman A, Friedl J, Lans T, Libutti S, Lorang D, Miller M . Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer. 2002; 99(1):149-53. DOI: 10.1002/ijc.10292. View

10.

Tanderup K, Georg D, Potter R, Kirisits C, Grau C, Lindegaard J . Adaptive management of cervical cancer radiotherapy. Semin Radiat Oncol. 2010; 20(2):121-9. DOI: 10.1016/j.semradonc.2009.11.006. View

11.

Pertl U, Luster A, Varki N, Homann D, Gaedicke G, Reisfeld R . IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J Immunol. 2001; 166(11):6944-51. DOI: 10.4049/jimmunol.166.11.6944. View

12.

Somasundaram K, El-Deiry W . Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene. 1997; 14(9):1047-57. DOI: 10.1038/sj.onc.1201002. View

13.

Schiffman M, Castle P . The promise of global cervical-cancer prevention. N Engl J Med. 2005; 353(20):2101-4. DOI: 10.1056/NEJMp058171. View

14.

Yang L, Wang B, Chen L, Luo H, Wu J . CXCL10 enhances radiotherapy effects in HeLa cells through cell cycle redistribution. Oncol Lett. 2012; 3(2):383-386. PMC: 3362509. DOI: 10.3892/ol.2011.472. View

15.

Pawlik T, Keyomarsi K . Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 2004; 59(4):928-42. DOI: 10.1016/j.ijrobp.2004.03.005. View

16.

Frosina G . DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res. 2009; 7(7):989-99. DOI: 10.1158/1541-7786.MCR-09-0030. View

17.

Bromley S, Mempel T, Luster A . Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol. 2008; 9(9):970-80. DOI: 10.1038/ni.f.213. View

18.

Kawauchi S, Yamamoto Y, Uchida K, Chochi Y, Kondo T, Oga A . Significance of cyclin E and p27 expression in malignant ovarian germ cell tumors: correlation with the cell proliferation activity and clinicopathologic features. Oncol Rep. 2006; 16(5):1029-33. View

19.

Arenberg D, Kunkel S, Polverini P, Morris S, Burdick M, Glass M . Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med. 1996; 184(3):981-92. PMC: 2192788. DOI: 10.1084/jem.184.3.981. View

20.

Wang L, Chen P, Luo S, Li J, Liu K, Hu H . CXC-chemokine-ligand-10 gene therapy efficiently inhibits the growth of cervical carcinoma on the basis of its anti-angiogenic and antiviral activity. Biotechnol Appl Biochem. 2009; 53(3):209-16. DOI: 10.1042/BA20090012. View